Achieving complete metabolic response in stage IV lung adenocarcinoma with chemotherapy, nivolumab, ipilimumab, and salvage SBRT: A case report

A 55-year-old male with stage IV oncogene-negative, PDL1-negative lung adenocarcinoma demonstrated a complete metabolic response to a novel treatment strategy. This regimen combined double immune checkpoint inhibition (ICI) with chemotherapy, followed by stereotactic body radiotherapy (SBRT), after initial partial response to two cycles of carboplatin, pemetrexed, nivolumab, and ipilimumab, plus maintenance with nivolumab and ipilimumab. This case underscores the effectiveness of integrating multiple treatment modalities for non-small cell lung cancer (NSCLC). AbstractOncogene-negative, PDL1-negative metastatic non-small cell lung cancer (NSCLC) presents significant treatment challenges due to its complexity and resistance to conventional therapies. The case report presented addresses a 55-year-old male patient with oncogene-negative, PDL1-negative stage IV lung adenocarcinoma, showcasing an exceptional complete metabolic response to a multimodality treatment combining double immune checkpoint inhibition (ICI) and chemotherapy, followed by salvage stereotactic body radiotherapy (SBRT). The patient underwent a treatment regimen incorporating two cycles of carboplatin, pemetrexed, nivolumab, and ipilimumab followed by nivolumab, and ipilimumab maintenance. After a partial response, SBRT was applied to persistent lesions, achieving a complete metabolic response. This case highlights the potential of combining dual ICI with chemotherapy and SBRT in treating oncogene-negative, PDL...
Source: Respirology Case Reports - Category: Respiratory Medicine Authors: Tags: CASE REPORT Source Type: research